Doxycycline Treatment in high-risk COVID patients: Recent Evidence
The SARS-CoV-2 infection continues to evolve with limited therapeutic options with the vaccine seemingly a few months still away. (1) In the meanwhile, there remains significant interest in repurposing existing, approved medications for the treatment of COVID-19. Amidst all the evidences that are clinically relevant, Doxycycline continues to remain a promising and potentially strong agent offering rational and safe management of COVID-19 patients.
Doxycycline in COVID 19 - Scientific Rationale
• For moderate to severe pneumonia in adults (>18 years) with suspected Community Acquired Pneumonia (CAP)
• For non-severe pneumonia in adults (>18 years) with suspected Hospital Acquired Pneumonia (HAP)